

AlaRS (AARS) Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP7558a

Specification

AlaRS (AARS) Antibody (N-term) Blocking peptide - Product Information

Primary Accession [P49588](#)

AlaRS (AARS) Antibody (N-term) Blocking peptide - Additional Information

Gene ID 16

Other Names

Alanine--tRNA ligase, cytoplasmic {ECO:0000255|HAMAP-Rule:MF_03133}, 6117
 {ECO:0000255|HAMAP-Rule:MF_03133}, Alanyl-tRNA synthetase
 {ECO:0000255|HAMAP-Rule:MF_03133}, AlaRS {ECO:0000255|HAMAP-Rule:MF_03133}, Renal
 carcinoma antigen NY-REN-42, AARS {ECO:0000255|HAMAP-Rule:MF_03133}

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7558a](/product/products/AP7558a) was selected from the N-term region of human AARS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AlaRS (AARS) Antibody (N-term) Blocking peptide - Protein Information

Name AARS1 {ECO:0000303|PubMed:38653238, ECO:0000312|HGNC:HGNC:20}

Function

Catalyzes the attachment of alanine to tRNA(Ala) in a two- step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043).

href="http://www.uniprot.org/citations/28493438" target="_blank">28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine residues in target proteins, such as TEAD1, TP53/p53 and YAP1 (PubMed:38512451, PubMed:38653238). Protein lactylation takes place in a two-step reaction: lactate is first activated by ATP to form lactate-AMP and then transferred to lysine residues of target proteins (PubMed:38512451, PubMed:38653238, PubMed:39322678). Acts as an inhibitor of TP53/p53 activity by catalyzing lactylation of TP53/p53 (PubMed:38653238). Acts as a positive regulator of the Hippo pathway by mediating lactylation of TEAD1 and YAP1 (PubMed:38512451).

Cellular Location

Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03133, ECO:0000269|PubMed:27911835, ECO:0000269|PubMed:38512451}. Nucleus. Note=Translocates to the nucleus in response to increased levels of lactate; nuclear translocation is dependent on KPNA4.

AlaRS (AARS) Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

AlaRS (AARS) Antibody (N-term) Blocking peptide - Images

AlaRS (AARS) Antibody (N-term) Blocking peptide - Background

The human alanyl-tRNA synthetase (AARS) belongs to a family of tRNA synthetases, of the class II enzymes. Class II tRNA synthetases evolved early in evolution and are highly conserved. This is reflected by the fact that 498 of the 968-residue polypeptide human AARS shares 41% identity with the E. coli protein. tRNA synthetases are the enzymes that interpret the RNA code and attach specific amino acids to the tRNAs that contain the cognate trinucleotide anticodons. They consist of a catalytic domain which interacts with the amino acid acceptor-T psi C helix of the tRNA, and a second domain which interacts with the rest of the tRNA structure.

AlaRS (AARS) Antibody (N-term) Blocking peptide - References

Shiba, K., Biochemistry 34 (33), 10340-10349 (1995) Ripmaster, T. L., Proc. Natl. Acad. Sci. U.S.A. 92 (11), 4932-4936 (1995) Sang Lee, J., Cell 127 (3), 635-648 (2006)